Compare ATGL & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | TARA |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 269.8M |
| IPO Year | 2023 | 2014 |
| Metric | ATGL | TARA |
|---|---|---|
| Price | $12.30 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 2.3K | ★ 669.9K |
| Earning Date | 01-27-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.01 | $2.77 |
| 52 Week High | $50.00 | $7.82 |
| Indicator | ATGL | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 40.08 |
| Support Level | $9.75 | $3.62 |
| Resistance Level | $20.25 | $5.53 |
| Average True Range (ATR) | 1.31 | 0.24 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 31.12 | 34.60 |
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.